- Interim (12-week) DARRT-1 readout
- Combination Veyonda + low-dose radiotherapy well tolerated
- PSA, pain and tumour responses at higher doses
- 24-week readout to indicate longevity of response.
SYDNEY, February 6, 2019: Noxopharm (ASX:NOX) announces interim (12-week) results from the dose-ranging component of the DARRT-1 study.
For further information please download PDF attached:
Download this document
